Trunk Quoted on OIG Guidance to Drugmakers for Planned TrumpRx Site
Law360 Healthcare Authority
Life Sciences Industry Group Co-Leader Stephanie Trunk was quoted on the US Department of Health and Human Services’ Office of Inspector General (OIG) guidance that pharmaceutical manufacturers would face a “low risk” of violating federal anti-kickback laws when selling directly to patients through the planned TrumpRx site.
Stephanie said that though the guidance as helpful but not “earth-shattering,” adding that how the discounts are handled in practice will shape future legal analysis and guidance.
“I think there’s a lot of detail that needs to be worked out,” she said.
Read the full article here. (Subscription required)
Contacts
- Related Industries